media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The Two Sides of RMC-6236

Following Revolution’s announcement on April 13th of positive results from the Phase III clinical trial RASolute302 of its pan-RAS inhibitor RMC-6236 in previously treated metastatic pancreatic cancer patients, the drug has now announced the latest research progress in first-line treatment. In terms of efficacy, RMC-6236 continues to surprise the market, demonstrating impressive remission rates whether used as a monotherapy or in combination therapy, and bringing new expectations to the industry. However, the potential toxicity of RMC-6236 continues to emerge. In particular, in the RMC-GI-102 study of first-line combination chemotherapy, grade ≥3 adverse reactions accounted for as high as 73%. Currently, the impact of this safety hazard on the subsequent R&D layout of RMC-6236 is still unclear, but it has pointed out a clear direction for differentiated breakthroughs for subsequent competitors in the same field. 01 The Two Sides of RMC-6236 RMC-6236 is a two-sided unit. In terms of efficacy, it ...
- Source: drugdu
- 57
- May 12, 2026
A rare disease company was acquired for $4.1 billion.

Italian pharmaceutical company Angelini Pharma recently announced its acquisition of Catalyst, a US-based rare disease specialist, for $4.1 billion, aiming to capitalize on the lucrative US market. The two companies expect to close the deal in the third quarter. According to publicly available information, Catalyst was founded in 2002 and went public on NASDAQ in 2006. The company is patient-centric, focusing on the introduction, development, and commercialization of novel medicines for rare and intractable diseases. In 2025, Catalyst’s revenue reached $589 million, a 20% increase, and this year’s revenue is projected to be between $615 million and $645 million. It has three products already on the market: Firdapse (amifampridine) is the company’s flagship product. It is the only evidence-based treatment approved by the FDA for Lambert-Eaton myasthenic syndrome (LEMS) in patients aged 6 and older. Sales of this drug are projected to reach $358 million in 2025, a 17% year-on-year ...
- Source: drugdu
- 66
- May 12, 2026
BIO

Organiser：BIO Convention Time：June 22 – June 25, 2026 Address：111 W. Harbor Dr., San Diego, CA 92101 Exhibition hall：San Diego Convention Center Product range: Biotechnology and products, biopharmaceutical R&D achievements, biotechnology parks and industrial base development, applications of biotechnology in healthcare, food, agriculture, energy, environmental protection, as well as international marketing and academic promotion of biotech products, intellectual property protection, clinical research and trials, investment and financing, technology transfer, and more. About BIO： The BIO International Convention (commonly known as BIO) was founded in 1993 and serves as the annual conference of the Biotechnology Innovation Organization (BIO). It is the largest, most professional, and most influential biotechnology event in the world. BIO aims to support the development of the global biotechnology industry. Through sponsoring biotechnology projects and initiatives, the profits from the convention are reinvested back into the biotechnology sector. The event is not primarily trade-oriented; instead, it emphasizes a ...
- Source: drugdu
- 76
- May 12, 2026
Revenue Soars 34% — Why BeiGene Decisively Cut 6 Pipeline Programs?

On May 8, BeiGene officially released its Q1 2026 financial results. Against the backdrop of overall pressure on China’s innovative drug industry and increasingly intense competition in R&D and commercialization, the company’s revenue performance bucked the trend and exceeded market expectations. Even more striking and industry-shaking, the company simultaneously announced a major pipeline strategy adjustment — terminating six investigational programs at once, covering five hot oncology targets and one autoimmune disease pipeline, signaling a clear strategic retrenchment. This “amputation-style” strategic adjustment marks the official end of China’s innovative drug leader’s past “land-grab” expansion model, fully transitioning to a new stage of high-quality development centered on “precision focus, efficient investment, and quality first,” setting a benchmark for industry transformation. I. Core Products Continue to Drive Growth, Commercialization Capabilities Re-validated Key financial data shows that in Q1 2026, BeiGene’s global product revenue reached US$1.5 billion, a substantial 34% year-over-year increase, demonstrating strong ...
- Source: drugdu
- 80
- May 11, 2026
InxMed Bio Partners with Fosun Pharma — Deal Worth RMB 1.115 Billion

On May 8, 2026, InxMed Biotechnology (Nanjing) Co., Ltd. announced a strategic partnership with Fosun Pharma. Under the agreement, InxMed Bio will grant Fosun Pharma the exclusive rights for sales, promotion, and full-channel commercialization of its two self-developed innovative FAK inhibitors, IN10018 (Ifebemtinib) and IN10028, in mainland China (excluding Hong Kong, Macau, and Taiwan). As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance. As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance. IN10018 is an innovative small-molecule FAK inhibitor with dual regulatory functions — kinase catalytic and protein scaffold — that exerts anti-tumor effects through multiple mechanisms including oncogenic pathway modulation and inhibition of tumor proliferation and invasion. The product ...
- Source: drugdu
- 72
- May 11, 2026
【EXPERT Q&A】What factors should be focused on when analyzing the benefits and risks of medical devices?

Drugdu.com expert’s response: The benefit-risk analysis of medical devices is a core component in ensuring their safety and effectiveness, requiring a comprehensive consideration of multidimensional factors encompassing science, clinical practice, ethics, and society. The following are the key factors that should be prioritized during the analysis: I. Intended Use and Performance of Medical Devices Target Patient Population Clearly define the age, gender, disease stage, or health status of patients for whom the device is suitable (e.g., children, pregnant women, elderly individuals, or patients with specific diseases). Evaluate differences in benefits and potential risks among different patient groups (e.g., children’s higher sensitivity to certain materials). Core Functions and Performance Indicators The primary therapeutic or diagnostic functions of the device (e.g., surgical robots, implantable cardiac pacemakers, in vitro diagnostic reagents). Accuracy, sensitivity, and specificity of performance parameters (e.g., false-positive/false-negative rates of diagnostic reagents). Reliability (e.g., mechanical failure rate, software stability) and durability ...
- Source: drugdu
- 70
- May 11, 2026
China Biopharmaceutical’s world-first innovative breast cancer treatment drug approved for first-line treatment indication

On May 6, Cumoxicillin Capsules (Saitanxin®), the world’s first CDK2/4/6 inhibitor independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of China Biopharmaceutical (01177.HK), received approval from the National Medical Products Administration (NMPA) for its combination with fulvestrant for the initial treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This is the second indication approved for the marketing of Cumoxicillin Capsules, providing a new treatment option for first-line treatment of HR-positive advanced breast cancer patients in China. Last December, cumoxicillin was approved in combination with fulvestrant for the treatment of HR+/HER2- breast cancer patients whose disease has progressed after prior endocrine therapy, and it is estimated that it has already benefited thousands of breast cancer patients in clinical practice. This new approval is primarily based on the CULMINATE-2 clinical trial, which showed that cumoxicillin in ...
- Source: drugdu
- 91
- May 9, 2026
The Phase III monotherapy clinical trial of Lianhuan Pharmaceutical’s LH-1801 tablets has been unblinded.

On the evening of May 7th, Lianhuan Pharmaceutical…(600513) issued an announcement stating that the Phase III monotherapy clinical trial of the Class 1 new drug LH-1801 tablets organized by the company has been unblinded and preliminary analysis results of the main data have been obtained recently. The announcement indicates that LH-1801 tablets are a novel SGLT-2 inhibitor, developed by Lianhuan Pharmaceutical in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and possessing independent intellectual property rights in China.A new antidiabetic drug, indicated for type 2 diabetes. https://finance.eastmoney.com/a/202605073730257969.html
- Source: drugdu
- 78
- May 9, 2026
Shian Biotech and GSK reach licensing collaboration worth over $1 billion on oligonucleotide drugs

Recently , GlaxoSmithKline (GSK) and SiranBio (hereinafter referred to as “SiranBio”) reached a global exclusive licensing agreement for the investigational small interfering RNA (siRNA) oligonucleotide SA030. GSK will pay Shian Biotech an upfront payment and up to US$1.005 billion in development, registration and commercialization milestone payments, as well as tiered royalties based on global net sales (excluding mainland China, Hong Kong, Macau and Taiwan). SA030 is currently in Phase I clinical trials and targets activin receptor-like kinase 7 (ALK7) for the treatment of metabolic and cardiovascular diseases. Its design target avoids the weight loss market and targets the most difficult-to-treat abdominal visceral fat. According to International Pharmaceutical Business News, this is the second time in nearly six months that GSK has acquired siRNA assets from a Chinese biotechnology company. In the previous transaction, GSK acquired two siRNA drug candidates for respiratory, immune and inflammation (RI&I) fields from Frontier Biotechnologies for ...
- Source: drugdu
- 76
- May 9, 2026
Is CAR-T cells forming bubbles in the body?

Following its $2.4 billion acquisition of Orna Therapeutics earlier this year, Eli Lilly is once again betting heavily on in vivo CAR-T therapy. Recently, Eli Lilly announced its acquisition of Kelonia Therapeutics for $7 billion, pushing the valuation of transactions in the in vivo CAR-T field to a new high. This means that by 2026, Eli Lilly will have invested nearly $10 billion in the in vivo CAR-T field alone. It’s worth noting that this acquisition doesn’t involve mature assets. Kelonia’s core drug, KLN-1010, is still in Phase I, with only early validation completed in four patients. Orna’s core asset, ORN-252, is in the clinical trial preparation stage. Clearly, Eli Lilly is not betting on a single molecule, but rather on two differentiated in vivo CAR-T technology pathways. Orna uses an LNP delivery + circular RNA system, which has advantages in in vivo stability and sustained protein expression, making it ...
- Source: drugdu
- 72
- May 9, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.